Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.32 |
| ▸ | ADH1B | P00325 | 1/20 | 0.31 |
| ▸ | ADH1A | P07327 | 1/20 | 0.31 |
| ▸ | ADH7 | P40394 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL840402 | 0.97 | ALDH1A1 (0.35) | ALDH1A1TSHRPAOXADH1BADH1A | |
| SCHEMBL2255609 | 0.83 | — | — | |
| SCHEMBL18766847 | 0.82 | TSHR (0.43) | ALDH1A1TSHRPAOX | |
| SCHEMBL29547823 | 0.80 | TSHR (0.48) | ALDH1A1TSHRPAOXADH1BADH1A | |
| SCHEMBL841332 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL128444 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL27289882 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL5385478 | 0.76 | ADH1B (0.32) | ADH1BADH1AADH7 | |
| Hydrochloric Acid SCHEMBL4320782 | 0.76 | TSHR (0.35) | ALDH1A1TSHRPAOXADH1BADH1A | |
| Hydrochloric Acid SCHEMBL1677526 | 0.73 | XPO1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7244746-B2 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-17 | — | — | US | disclosed |
| US-7238699-B2 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-03 | — | — | US | disclosed |
| US-7211669-B2 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-01 | — | — | US | disclosed |
| US-7125990-B2 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-24 | — | — | US | disclosed |
| US-6888004-B2 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-03 | — | — | US | disclosed |
| US-20040254382-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-16 | — | — | US | disclosed |
| US-20040235924-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-25 | — | — | US | disclosed |
| US-20040225130-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-11 | — | — | US | disclosed |
| US-20040225001-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-11 | — | — | US | disclosed |
| EP-1359916-A4 | IMIDAZOLYL DERIVATIVES AS CORTICOTROPIN RELEASING FACTOR INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2004-04-07 | — | — | EP | disclosed |
| EP-1320365-A4 | SUBSTITUTED AZOLE DERIVATIVES AS INHIBITORS OF CORTICOTROPIN RELEASING FACTOR | BRISTOL MYERS SQUIBB CO (US) | 2004-03-17 | — | — | EP | disclosed |
| EP-1359916-A1 | IMIDAZOLYL DERIVATIVES AS CORTICOTROPIN RELEASING FACTOR INHIBITORS | Bristol-Myers Squibb Company (US) | 2003-11-12 | — | — | EP | disclosed |
| EP-1320365-A1 | SUBSTITUTED AZOLE DERIVATIVES AS INHIBITORS OF CORTICOTROPIN RELEASING FACTOR | Bristol-Myers Squibb Company (US) | 2003-06-25 | — | — | EP | disclosed |
| US-6515005-B2 | For treatment of depression, anxiety, feeding disorders, headache, drug addiction, inflammatory disorders | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-04 | — | — | US | disclosed |
| US-20020183375-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-12-05 | — | — | US | disclosed |
| US-20020161019-A1 | Substituted azole derivatives as inhibitors of corticotropin releasing factor | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-31 | — | — | US | disclosed |
| WO-2002058704-A1 | IMIDAZOLYL DERIVATIVES AS CORTICOTROPIN RELEASING FACTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002024200-A1 | SUBSTITUTED AZOLE DERIVATIVES AS INHIBITORS OF CORTICOTROPIN RELEASING FACTOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040225001-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | CRH, CRHR1, CRHR2 | ALDH1A1 2593/4885TSHR 65/4885PAOX 2540/4885 |
| US-20020161019-A1 | Substituted azole derivatives as inhibitors of corticotropin releasing factor | CRH, CRHR1, CRHR2 | ALDH1A1 1902/4885TSHR 62/4885PAOX 1700/4885 |
| US-20040225130-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | CRH, CRHR1, CRHR2 | ALDH1A1 2593/4885TSHR 65/4885PAOX 2540/4885 |
| US-20020183375-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | CRH, CRHR1, CRHR2 | ALDH1A1 2593/4885TSHR 65/4885PAOX 2540/4885 |
| US-20040254382-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | CRH, CRHR1, CRHR2 | ALDH1A1 2593/4885TSHR 65/4885PAOX 2540/4885 |
| US-20040235924-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | CRH, CRHR1, CRHR2 | ALDH1A1 2593/4885TSHR 65/4885PAOX 2540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.